Memory Deterioration in Alzheimer Disease

N/ARecruitingNCT07118137

Norwegian University of Science and Technology30 enrolled

Overview

Semantic AD

Study Type

OBSERVATIONAL

Enrollment

Conditions

Alzheimer Disease Neurodegenerative Diseases Magnetic Resonance Imaging Memory Impairment

Interventions

7T MRIDEVICE

Resting and activity-based MRI. Dring activity based MRI, the participant will complete tasks testing semantic memory.

EEGDEVICE

Resting-state EEG

Blood samplesBIOLOGICAL

Blood samples taken for analysis of central blood biomarkers.

Eligibility

Sex: ALLMin age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed diagnosis based on current ICD criteria for AD or MCI . * \>55years. * Norwegian native speaker * Lives at home and not in a health institution Exclusion Criteria: * Patients with severe cognitive impairment that prevents assessment with the selected modalities (planned cut-off: CDR \> 2). * Presence of brain tumors. * History of traumatic brain injury. * History of cranial surgery. * Contraindications to the selected imaging modalities (e.g., 7T MRI or EEG). * Diagnosis of other neurodegenerative diseases such as Parkinson's disease or ALS. 7T MRI contraindications: * Large tattoos close to the head region, permanent makeup or unremoveable piercings * Certain models of pacemakers (if pacemaker implantet, MRI physicist at 7T-lab will be conferred) * Implantet metal in body (clips, stents, prothesis, skrews, plates, teeth etc.)

Locations (1)

Norwegian University of Sciene and Technology / Norges teknisk-naturvitenskapelige universitet (NTNU)

Trondheim, Trønderlag, Norway

RECRUITING

Outcomes

Primary Outcomes

Understand which individual differences are observed among patients with Alzheimer's disease (AD).

This outcome will characterize individual variability among patients diagnosed with Alzheimer's disease based on clinical symptoms, cognitive assessments, neuroimaging findings (7T MRI), electrophysiological data (EEG), and biological samples (blood and stool). The goal is to identify patterns or subtypes that may reflect distinct disease mechanisms or progression profiles.

Time frame: From enrollment to end of follow-up at 1 year.

Compare changes in the brain, blood, and stool samples between dementia patients and healthy controls.

Assess differences between dementia patients and cognitively healthy controls using multimodal data, including 7T MRI for brain structure, EEG, blood biomarkers, and gut microbiome profiles from stool samples. The aim is to identify biological and neurological markers associated with dementia-related changes.

Time frame: From project enrollment to end of follow-up at 1 year.

Secondary Outcomes

Understand which individuals with mild cognitive impairment (MCI) go on to develop Alzheimer's disease (AD).

Identify early clinical, neuroimaging, and biological markers associated with progression from MCI to AD. This research question aims to improve early diagnosis and risk stratification in individuals with MCI.

Time frame: From enrollment to the end of follow-up time at 1 year.

Central Contacts

Axel Sandvig Professor, MD & PhD

CONTACT

+4745840578 axel.sandvig@ntnu.no

Varanann Varathalingam

CONTACT

varananv@ntnu.no

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.